Scarica l'app Stockscreener
14.19
7.25%
-1.11
Contineum Therapeutics Inc Borsa (CTNM) Ultime notizie
Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - marketbeat.com
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 4.9%What's Next? - marketbeat.com
Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% HigherShould You Buy? - marketbeat.com
(CTNM) Risk Channels and Responsive Allocation - Stock Traders Daily
Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Nigeria
Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise - Stock Titan
CTNM (CTNM) insider schedules 2,500-share stock sale after recent 10b5-1 trades - Stock Titan
CTNM (CTNM) insider Daniel Lorrain files to sell 9,520 common shares - Stock Titan
Contineum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Perceptive Advisors LLC Has $16.40 Million Stake in Contineum Therapeutics, Inc. $CTNM - marketbeat.com
RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com
Contineum reports $15.2 million second quarter loss - Quiver Quantitative
Contineum Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView
Contineum Therapeutics reports Q2 2026 net loss $15.2M; cash and marketable securities $236.6M - TradingView
CTNM|Contineum Therapeutics Inc|Price:15.040|Chg%:-0.310 - TradingKey
Contineum Therapeutics, Inc. Revenue Breakdown – NASDAQ:CTNM - TradingView
BlackRock (CTNM stakeholder) reports 2.0M-share beneficial position in Therapeutics Inc - Stock Titan
CTNM|Contineum Therapeutics Inc|Price:15.390|Chg%:-0.510 - TradingKey
Contineum Therapeutics Inc (CTNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Contineum Therapeutics Inc (CTNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Contineum Therapeutics Inc (CTNM) Institutional Confidence - TradingKey
Contineum Therapeutics Inc (CTNM) Balance Sheet - TradingKey
Contineum Therapeutics Market Sentiment - Benzinga España
TradingKey - TradingKey
Contineum Therapeutics Inc (CTNM) Income Statement - TradingKey
CTNM|Contineum Therapeutics Inc|Price:13.835|Chg%:-0.225 - TradingKey
Millennium Management LLC Reduces Stake in Contineum Therapeutics Inc - GuruFocus
Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise, Stock Pulls BackEPS Growth Rate - dars.gov.et
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Contineum Therapeutics (CTNM) stake at 2.8% in Millennium 13G/A update - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ: CTNM) Stock Price, News & Analysis - Kalkine
Liquidity Mapping Around (CTNM) Price Events - Stock Traders Daily
Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership - The Globe and Mail
Contineum Therapeutics updates corporate presentation; highlights PIPE-791 progress, cash runway through mid-2029 - TradingView
Contineum Therapeutics (NASDAQ: CTNM) details PIPE-791 IPF trial and PIPE-307 deal - Stock Titan
CTNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals ProgressRevenue Beat Analysis - dars.gov.et
Contineum Therapeutics (CTNM) Slips Amidst Sector Pressures – Key Levels in FocusCash Flow Strong Stocks - dars.gov.et
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock - Investing.com UK
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com - Investing.com Nigeria
Form 4 Contineum Therapeutics Inc For: 10 July By Investing.com - Investing.com Nigeria
Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options - Stock Titan
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice - MSN
Form 4 Contineum Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Contineum Therapeutics CEO Stengone sells $40,000 in shares By Investing.com - Investing.com South Africa
Price to sales forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Contineum Therapeutics CEO Stengone sells $40,000 in shares - Investing.com
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):